Dr Mark Treherne

Drug discovery

  • A PhD drug discovery and development scientist specialising in oncology Alzheimer’s, Parkinson’s & other neurodegenerative diseases.

  • Over 25 years industrial R&D experience: drugs, natural products, devices & biologics to treat diseases of unmet need.

  • Raised over £200 million for private and public companies.

  • International investment, out licensing, general business development and M&A experience.

  • Director of 20 companies in UK, US, France, Australia, Denmark, Norway  and the Netherlands, including being Chief Executive of Cambridge Drug Discovery, Commercial Director of BioFocus plc, and Chief Executive of Senexis, Avilex and Cellesce.

  • Director of public companies and served on audit & remuneration committees.

  • Managed large and small multidisciplinary teams internally and through strategic outsourcing, specialising in contract pricing.

  • Mark is currently Chairman of two drug discovery services providers, Talisman Therapeutics and Ubiquigent, as well as NuVision Biotherapies, which is a regenerative medicine company. Mark is also a non-executive director of Cell Guidance Systems, a research tools and services company that enables the control, manipulation and monitoring of cells.

  • From 2012 – 2016, Mark was the Chief Executive of the Life Science Organisation of UKTI: he set up the new organisation at the request of 10 Downing Street to promote inward investment and trade, delivering over £6 billion in inward investment, creating and safeguarding 17,000 jobs. A particular focus was the application of digital technologies in healthcare systems.